Added to YB: 2024-02-02
Pitch date: 2024-02-01
CRBU [bullish]
Caribou Biosciences, Inc.
-69.62%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Market Cap
$190.6M
Pitch Price
$6.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.86
P/E
-1.37
EV/Sales
8.83
Sector
Biotechnology
Category
growth
Show full summary:
Caribou Biosciences: Under The Radar With Catalysts Approaching
CRBU a strong buy: Positive off-the-shelf CAR-T CB-010 progress, pivotal trial for 2L LBCL by YE24. More ANTLER data Q2, CB-011 MM data YE24. Manageable toxicity, effective lower doses. CB-012 clinical H1. $370M+ cash YE23, EV <$200M. Risks: Weak ANTLER/CB-011 data, CB-012 tox.
Read full article (4 min)